ArticleJournal of animal science and biotechnology2026
Magnolol enhances yak oocyte maturation and blastocyst quality by improving lipid metabolism and redox homeostasis through a PPARγ-dependent mechanism.
Article in Journal of animal science and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundReproductive efficiency in yaks is limited by the poor developmental competence of their oocytes during in vitro maturation (IVM). Magnolol (MAG), a natural polyphenolic compound with potent antioxidant activity, has been reported to regulate cellular metabolism and oxidative stress; however, its role in oocyte maturation and early embryonic development remains unclear. Therefore, this study investigated the effects and molecular mechanisms of MAG on yak oocyte maturation and developmental competence.
methodsYak cumulus-oocyte complexes were cultured in IVM medium supplemented with different concentrations of MAG (0, 0.5, 1, 5, and 10 μmol/L). Oocyte maturation, cumulus expansion, oxidative stress indicators, mitochondrial function, apoptosis, and lipid metabolism were evaluated using fluorescence staining, qPCR, and immunofluorescence analysis. Network pharmacology and molecular docking were used to predict potential targets of MAG, and the peroxisome proliferator-activated receptor gamma (PPARγ) antagonist GW9662 was applied to verify the regulatory mechanism occurring during IVM and subsequent embryo development.
resultsBased on the concentration-screening results, 1 μmol/L MAG was selected for subsequent mechanistic and embryo-development analyses. MAG supplementation significantly improved oocyte maturation and cumulus expansion, enhanced glutathione levels and mitochondrial membrane potential, and reduced reactive oxygen species accumulation and apoptosis. MAG also promoted lipid droplet accumulation and upregulated the expression of lipid metabolism-related genes, including PPARG, CD36, FABP3, and FABP4. Network pharmacology identified PPARγ as a key target of MAG. Pharmacological inhibition of PPARγ with GW9662 markedly reversed MAG-induced improvements in lipid metabolism, antioxidant capacity, and oocyte developmental competence. Furthermore, MAG increased blastocyst formation rate, total cell number, and CDX2 expression while reducing the blastocyst apoptosis.
conclusionMAG improves yak oocyte quality and embryonic developmental competence by promoting lipid homeostasis, maintaining redox balance, and enhancing mitochondrial function. The beneficial effects of MAG are closely associated with the involvement of PPARγ signaling in the regulation of lipid homeostasis. These findings provide a potential strategy for improving the efficiency of yak assisted reproductive technologies.
Indexed as
Identifiers
42823744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.